Determination That SODIUM FLUORIDE F 18 (Sodium Fluoride F-18) Injection, 10 to 200 Millicuries per Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
Health and Human Services Department; Food and Drug Administration · 2011
Read Determination That SODIUM FLUORIDE F 18 (Sodium Fluoride F-18) Injection, 10 to 200 Millicuries per Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness by Health and Human Services Department; Food and Drug Administration (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/uslaw-fr-2011-15815.txt.
Description
Notice published in the Federal Register on 2011-06-24 by Health and Human Services Department; Food and Drug Administration. Text from federalregister.gov (official edition: govinfo). [FR Doc No: 2011-15815] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2011-N-0428] Determination That SODIUM FLUORIDE F 18 (Sodium Fluoride F-18) Injection, 10 to 200 Millicuries per Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness AGENCY: Food and.
Catalog record
| CREATOR | Health and Human Services Department; Food and Drug Administration |
|---|---|
| YEAR | 2011 |
| COLLECTION | LAW |
| FORMAT | TXT |
| FILE SIZE | 6 KB |
| VERSION | 1.0 |
| LICENSE | Public Domain |
| RIGHTS | PUBLIC DOMAIN |
| SOURCE | Federal Register |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Determination That SODIUM FLUORIDE F 18 (Sodium Fluoride F-18) Injection, 10 to 200 Millicuries per Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
Citation: us:fr:2011-15815
Creator: Health and Human Services Department; Food and Drug Administration
Year: 2011
Source-URL: https://www.federalregister.gov/documents/2011/06/24/2011-15815/determination-that-sodium-fluoride-f-18-sodium-fluoride-f-18-injection-10-to-200-millicuries-per
Context: Notice published in the Federal Register on 2011-06-24 by Health and Human Services Department; Food and Drug Administration. Text from federalregister.gov (official edition: govinfo).
[FR Doc No: 2011-15815]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2011-N-0428]
Determination That SODIUM FLUORIDE F 18 (Sodium Fluoride F-18)
Injection, 10 to 200 Millicuries per Milliliter, Was Not Withdrawn From
Sale for Reasons of Safety or Effectiveness
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) has determined that
SODIUM FLUORIDE F 18 (sodium fluoride F-18) injection, 10 to 200
millicuries per milliliter (mCi/mL), was not withdrawn from sale for
reasons of safety or effectiveness. This determination will allow FDA
to approve abbreviated new drug applications (ANDAs) for SODIUM
FLUORIDE F 18 injection, 10 to 200 mCi/mL, if all other legal and
regulatory requirements are met.
FOR FURTHER INFORMATION CONTACT: Reena Raman, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, rm. 6238, Silver Spring, MD 20993-0002, 301-
796-7577.
SUPPLEMENTARY INFORMATION: In 1984, Congress enacted the Drug Price
Competition and Patent Term Restoration Act of 1984 (Pub. L. 98-417)
(the 1984 amendments), which authorized the approval of duplicate
versions of drug products under an ANDA procedure. ANDA applicants
must, with certain exceptions, show that the drug for which they are
seeking approval contains the same active ingredient in the same
strength and dosage form as the ``listed drug,'' which is a version of
the drug that was previously approved. ANDA applicants do not have to
repeat the extensive clinical testing otherwise necessary to gain
approval of a new drug application (NDA). The only clinical data
required in an ANDA are data to show that the drug that is the subject
of the ANDA is bioequivalent to the listed drug.
The 1984 amendments include what is now section 505(j)(7) of the
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7)), which
requires FDA to publish a list of all approved drugs. FDA publishes
this list as part of the ``Approved Drug Products With Therapeutic
Equivalence Evaluations,'' which is known generally as the ``Orange
Book.'' Under FDA regulations, drugs are removed from the list if the
Agency withdraws or suspends approval of the drug's NDA or ANDA for
reasons of safety or effectiveness or if FDA determines that the listed
drug was withdrawn from sale for reasons of safety or effectiveness
(Sec. 314.162 (21 CFR 314.162)).
A person may petition the Agency to determine, or the Agency may
determine on its own initiative, whether a listed drug was withdrawn
from sale for reasons of safety or effectiveness. This determination
may be made at any time after the drug has been withdrawn from sale but
must be made prior to approving an ANDA that refers to the listed drug
(21 CFR 314.161). FDA may not approve an ANDA that does not refer to a
listed drug.
SODIUM FLUORIDE F 18 (sodium fluoride F-18) injection, 10 to 200
mCi/mL, is the subject of NDA 22-494, held by National Cancer
Institute, National Institutes of Health, and initially approved on
January 26, 2011. SODIUM FLUORIDE F 18 (sodium fluoride F-18) is
indicated for diagnostic positron emission tomography imaging of bone
to define areas of altered osteogenic activity.
The NDA holder has never marketed SODIUM FLUORIDE F 18 (sodium
fluoride F-18) injection, 10 to 200 mCi/mL, and in a letter dated May
2, 2011, the NDA holder requested that FDA move the product to the
``Discontinued Drug Product List'' section of the Orange Book. In
previous instances (see, e.g., 72 FR 9763, March 5, 2007; 61 FR 25497,
May 21, 1996), the Agency has determined that, for purposes of
Sec. Sec. 314.161 and 314.162, never marketing an approved drug
product is equivalent to withdrawing the drug from sale.
FDA has reviewed its records and, under Sec. 314.161, has
determined that SODIUM FLUORIDE F 18 (sodium fluoride F-18) injection,
10 to 200 mCi/mL, was not withdrawn from sale for reasons of safety or
effectiveness. Accordingly, the Agency will continue to list SODIUM
FLUORIDE F 18 (sodium fluoride F-18) injection, 10 to 200 mCi/mL, in
the ``Discontinued Drug Product List'' section of the Orange Book. The
``Discontinued Drug Product List'' delineates, among other items, drug
products that have been discontinued from marketing for reasons other
than safety or effectiveness. ANDAs that refer to SODIUM FLUORIDE F 18
(sodium fluoride F-18) injection, 10 to 200 mCi/mL, may be approved by
the Agency as long as they meet all other legal and regulatory
requirements for the approval of ANDAs. If FDA determines that labeling
for this drug product should be revised to meet current standards, the
Agency will advise ANDA applicants to submit such labeling.
Dated: June 20, 2011.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2011-15815 Filed 6-23-11; 8:45 am]